Background: The mortality rates of early-onset colorectal cancer (EOCRC) have surged globally over the past two decades. While the underlying reasons remain largely unknown, understanding its epidemiology is crucial to address this escalating trend. This study aimed to identify disparities potentially influencing these rates, enhancing risk assessment tools, and highlighting areas necessitating further research. Methods: Using the CDC Wide-Ranging Online Data for Epidemiologic Research (WONDER) database, this study assessed EOCRC mortality data from 2012 to 2020. Individuals under 50 years who succumbed to EOCRC were identified through the International Classification of Diseases, Tenth Revision (ICD-10) codes. Data interpretation and representation were performed using R 4.2.2 software. Results: Between 2012 and 2020, EOCRC mortality rates fluctuated marginally between 1.7 and 1.8 per 100,000. Male mortality rates increased from 1.9 to 2.0 per 100,000, while female rates varied between 1.5 and 1.6 per 100,000. Significant variations were observed across age groups, with the 40–49 years category experiencing an increase from 6.34 (2012) to 6.94 (2020) per 100,000. Racial category-based data revealed the highest mortality rates among African Americans. Geographically, Mississippi and Alabama exhibited elevated mortality rates. Age-adjusted mortality rate (AAMR) assessments indicated a marked decline for both genders from 2012 to 2020, with consistently higher rates for men. Conclusion: The findings highlight the evolving landscape of EOCRC mortality, revealing significant gender, age, and racial disparities. These results underscore the urgent need for tailored health strategies and intensified research efforts targeting these disparities.

Background. Establishing prompt vascular access facilitates resuscitation for out-of-hospital cardiac arrest (OHCA). While intraosseous access may decrease the time to vascular access, the impact on clinical outcomes in OHCA is unclear. Therefore, we aim to compare the effect of intraosseous (IO) versus intravenous (IV) vascular access on clinical outcomes after OHCA resuscitation. Methods. A systematic review and meta-analysis were performed to synthesize evidence from randomized controlled trials (RCTs) obtained from PubMed, CENTRAL, Scopus, and Web of Science until January 2025. Using Stata MP v. 17, we used the fixed-effects model to report dichotomous outcomes using the risk ratio (RR) and continuous outcomes using the mean difference (MD) with a 95% confidence interval (CI). PROSPERO ID: CRD42024627354. Results. Four RCTs and 9475 patients were included. There was no difference between both groups regarding the prehospital return of spontaneous circulation (ROSC) (RR: 0.97, 95% CI [0.91, 1.03], p = 0.33), maintained ROSC (RR: 0.94, 95% CI [0.87, 1.01], p = 0.09), survival to discharge (RR: 1.03 with 95% CI [0.88, 1.21], p = 0.71), 30-day survival (RR: 0.98, 95% CI [0.82, 1.17], p = 0.79), or favorable neurological recovery (RR: 1.07, 95% CI [0.90, 1.29], p = 0.44). However, IO access significantly increased first-attempt access (RR: 1.24, 95% CI [1.19, 1.29], p < 0.001), decreased time to vascular access (MD: −0.24 min with 95% CI [−0.48, −0.01], p = 0.04), and decreased time to drug administration (MD: −0.38, 95% CI [−0.66, −0.10], p = 0.01). Conclusions. IO and IV vascular accesses showed similar clinical outcomes in OHCA patients, with no difference in ROSC, survival, or neurological recovery. Still, IO access showed a better procedural outcome with increased first-attempt success rates, faster access, and faster drug administration.

This report describes a patient with Pasteurella multocida pneumonia. The patient was a man in his 70s with significant comorbid conditions, including chronic obstructive pulmonary disease (COPD), and is an example of the diverse presentations of P. multocida infections increasingly found in the literature. The novelty of this case lies in the manifestation of P. multocida pneumonia in a patient with underlying respiratory conditions and its successful management, outlining a unique clinical scenario and a tailored therapeutic approach. A 71-year-old male with a medical history of COPD, asthma, tremors, hypertension, and arthritis presented to the emergency department with progressive shortness of breath, productive cough, and chest tightness. The initial diagnosis was COPD exacerbation and left lower lobe pneumonia, for which a regimen of ceftriaxone and azithromycin was initiated. The patient's condition was further complicated by the persistence of symptoms. Following sputum culture analysis, P. multocida infection was identified. Consequently, the antibiotic regimen was tailored, transitioning the patient to doxycycline, which led to substantial clinical improvement, enabling discharge with a 10-day course of oral doxycycline. This case elucidates the importance of precise microbiological diagnosis in patients with complex respiratory conditions, as it guides more targeted antibiotic therapy. It highlights the need for clinical vigilance for atypical pathogens like P. multocida in patients with COPD exacerbations, especially when conventional treatment strategies yield suboptimal responses. The successful resolution of the pneumonia underscores the effectiveness of antibiotic stewardship guided by sputum culture findings.

INTRODUCTION: Irritable bowel syndrome (IBS) affects between 10% and 20% of the global population. The therapeutic effect of yoga on IBS symptoms has been investigated by several randomized controlled trials (RCTs) with inconsistent findings. We conducted this review to synthesize the current evidence on yoga's effect on IBS symptoms. METHODS: A systematic review and meta-analysis were performed through systematically searching PubMed, EMBASE, WOS, SCOPUS, and Cochrane through October 2024. Continuous variables were pooled using the standardized mean difference (SMD), with confidence intervals (CIs) using Stata MP version 17. We assessed heterogeneity using the χ ² test and I ² statistics. PROSPERO ID: CRD42024611633. RESULTS: Eleven RCTs with 535 patients were included. Seven RCTs included adults, 3 included pediatric or adolescent patients, and another included adolescents and young adults. The yoga intervention type varied among the included trials, with the program duration ranging from 6 weeks to 8 months and the session duration ranging from 40 to 90 minutes. There was no difference between yoga and control groups in alleviating the severity of gastrointestinal symptoms (SMD −0.66, with 95% CI −1.51 to 0.18, P = 0.12), anxiety (SMD −0.39, with 95% CI −0.85 to 0.06, P = 0.09), and depression (SMD −0.46, with 95% CI −1.15 to 0.22, P = 0.19) or improving quality of life (SMD 0.53, with 95% CI −0.38 to 1.44, P = 0.25). DISCUSSION: With uncertain evidence, yoga did not reduce the gastrointestinal severity of symptoms, anxiety, and depression or improve quality of life in patients with IBS. In light of the considerable methodological heterogeneity and the high risk of bias within the included RCTs, Yoga cannot be recommended as a treatment for IBS before conducting further large-scale RCTs to fill the current evidence gaps.

Rationale: Behçet disease (BD) is a chronic inflammatory vasculitis that primarily affects young males and is associated with severe vascular complications. Prolonged nonsteroidal anti-inflammatory drug (NSAID) use may mask early inflammatory signs, delaying diagnosis and appropriate treatment. Patient concerns: A 28-year-old pharmacist experienced syncope, chest pain, and leg swelling after prolonged NSAID use. Diagnoses: Workup revealed a left ventricular aneurysm, deep vein thrombosis, and multiple arterial occlusions, leading to the diagnosis of BD. Interventions: The patient received therapeutic anticoagulation, high-dose corticosteroids, cyclophosphamide, colchicine, and later azathioprine as maintenance. Surgical interventions included left ventricular aneurysmectomy and femoropopliteal bypass. Outcomes: The patient showed dramatic clinical improvement with resolution of oral ulcers, normalization of cardiac function, regression of thrombus, and improvement from New York Heart Association class IV to II at 1-month follow-up. No new thrombotic or vascular events occurred during subsequent years under maintenance immunosuppression. Lessons: This case underscores the life-threatening consequences of undiagnosed BD and highlights how NSAID overuse can obscure early inflammatory symptoms, delay immunosuppressive therapy, and lead to severe cardiac complications. Early recognition, cautious NSAID use, and a multidisciplinary approach are essential in managing BD-related vascular disease.